Estrone (E1): Evidence-Based Ways to Improve Your Number

What Estrone (E1) Actually Is

Estrone is one of three naturally occurring estrogens in the female body, alongside estradiol (E2) and estriol (E3). Of the three, estradiol is the most biologically active during the reproductive years. After menopause, estradiol production from the ovaries drops sharply, and estrone becomes the predominant circulating estrogen.

E1 is produced mainly through the conversion of androgens, particularly androstenedione, by an enzyme called aromatase. In premenopausal women, aromatase is active in the ovaries, liver, and other tissues. After menopause, adipose tissue becomes the primary aromatase site, which is why body composition has an outsized effect on postmenopausal E1 levels.

Why Estrone Is a Weaker Estrogen Than Estradiol

Estrone binds estrogen receptors with roughly one-third the affinity of estradiol. That lower potency matters clinically. A postmenopausal woman with measurable E1 still has less total estrogenic activity than a premenopausal woman with lower absolute estrogen levels, because the receptor binding is weaker. This distinction shapes how providers interpret your result and whether intervention is warranted.

How Estrone Differs From the Other Estrogens

| Estrogen | Primary source | Relative receptor potency | When it dominates | |---|---|---|---| | Estradiol (E2) | Ovaries | 1.0 (reference) | Reproductive years | | Estrone (E1) | Adipose aromatase | ~0.3 | Postmenopause | | Estriol (E3) | Placenta | ~0.01 | Pregnancy |

What a Normal Estrone (E1) Range Looks Like

Reference ranges vary by laboratory, assay method, and life stage. The numbers below reflect commonly cited clinical thresholds; always interpret your result against the specific reference range printed on your lab report.

Premenopausal Women

• Follicular phase: 17 to 200 pg/mL
• Luteal phase: 21 to 321 pg/mL
• Ovulatory peak: values may briefly exceed 200 pg/mL

These ranges are broad because E1 fluctuates with cycle phase. A single mid-cycle draw is rarely informative on its own.

Perimenopause

E1 levels become erratic during perimenopause. Estrone can remain in the normal or even elevated premenopausal range for years while estradiol begins to fall, because peripheral aromatization continues even as ovarian function declines. This dissociation means that an E1 result alone does not confirm or exclude perimenopause. FSH and estradiol measured together provide a clearer picture.

Postmenopause (No Hormone Therapy)

The expected range for women who are at least 12 months past their last period and not on hormone therapy is approximately 7 to 40 pg/mL. Values persistently above 40 pg/mL in a postmenopausal woman without exogenous estrogen use warrant investigation, particularly for obesity-driven excess aromatization or an estrogen-secreting tumor (rare).

Postmenopause (On Hormone Therapy)

Target ranges depend on the formulation and route. Oral estrogens tend to raise E1 disproportionately relative to E2 due to first-pass hepatic conversion. Transdermal estradiol produces a more physiologic E2-to-E1 ratio and is generally preferred for this reason in current prescribing practice.

What High Estrone Means for Your Health

An elevated E1 result, specifically one above the postmenopausal reference range in a woman not on hormone therapy, or a pattern of E1 consistently dominating over E2 in a premenopausal woman, is worth understanding in context.

Obesity and Adipose Aromatization

The most common driver of high postmenopausal E1 is excess adipose tissue. Fat cells contain aromatase, and more adipose means more androgen-to-estrogen conversion. A 2003 analysis published in the Journal of Clinical Endocrinology and Metabolism found that BMI was independently associated with higher circulating estrone concentrations in postmenopausal women, with levels rising roughly proportionally to fat mass.

This is clinically meaningful because elevated postmenopausal estrogen, including E1, is associated with increased breast cancer risk. The Women's Health Initiative observational data showed that postmenopausal women with higher endogenous estrogen levels had significantly elevated breast cancer incidence compared to those with lower levels, independent of exogenous hormone use.

PCOS and Androgen Excess

In premenopausal women with polycystic ovary syndrome (PCOS), elevated androgens can drive excess peripheral aromatization, pushing E1 higher relative to E2. PCOS affects approximately 8 to 13% of women of reproductive age worldwide and frequently presents with a distorted E1:E2 ratio alongside elevated testosterone and LH. If you have PCOS, an isolated E1 result needs to be read alongside the full hormonal panel your provider ordered.

Endometrial Implications

Estrone stimulates the endometrial lining. Chronically elevated E1 in the absence of adequate progesterone, a state called unopposed estrogen, can drive endometrial hyperplasia and, over time, increase endometrial cancer risk. ACOG Practice Bulletin No. 147 identifies unopposed estrogen exposure as a leading modifiable risk factor for endometrial cancer. For postmenopausal women on estrogen therapy, adequate progestogen opposition is required to protect the uterine lining.

What Low Estrone Means for Your Health

Low E1, below approximately 7 pg/mL in a postmenopausal woman, generally reflects minimal peripheral aromatization, often seen in women with very low body fat or those taking aromatase inhibitors for breast cancer treatment.

In premenopausal women, low E1 can accompany hypothalamic amenorrhea, premature ovarian insufficiency (POI), or anorexia nervosa. The consequence is the same regardless of cause: insufficient estrogenic stimulation of bone, cardiovascular tissue, brain, and the genitourinary tract.

Bone Health

Estrogen deficiency is the primary driver of accelerated bone loss in the years immediately surrounding menopause. The 2023 Menopause Society position statement on hormone therapy notes that women can lose 1 to 3% of bone density per year in early postmenopause without adequate estrogenic support. Even the weaker estrogenic activity of E1 contributes to bone maintenance; women with higher postmenopausal E1 tend to have better bone mineral density than those with undetectable levels.

Genitourinary Syndrome of Menopause (GSM)

GSM encompasses vaginal dryness, urinary urgency, and dyspareunia. These symptoms worsen as all estrogens fall. While local vaginal estradiol is the therapeutic standard for GSM, understanding your systemic E1 provides context for symptom severity.

Cardiovascular and Cognitive Effects

The evidence here is more nuanced. Estrogen has complex effects on the cardiovascular system that depend heavily on the timing of initiation relative to menopause. The "timing hypothesis" supported by the KEEPS trial suggests that estrogen started close to menopause may be cardioprotective, whereas late initiation may not confer the same benefit. Low E1 in early postmenopause may contribute to adverse lipid shifts and vascular changes, though E1 alone is not currently used as a standalone therapeutic target for cardiovascular risk.

How to Lower Estrone (E1): Evidence-Based Approaches

If your postmenopausal E1 is elevated and your provider has determined this warrants intervention, the primary levers are body composition and, in specific oncologic contexts, pharmacologic aromatase inhibition.

1. Reduce Adipose Tissue Through Sustained Weight Loss

Because adipose aromatase drives postmenopausal E1, weight loss is the most evidence-backed behavioral intervention. A randomized controlled trial in the Journal of Clinical Oncology found that a 10% reduction in body weight in postmenopausal women produced a statistically significant decrease in circulating estrone and estradiol concentrations. The effect was dose-dependent: greater weight loss produced greater estrogen reduction.

Aerobic exercise combined with caloric restriction achieves larger and more durable reductions than exercise alone.

2. Prioritize Fiber and Reduce Refined Carbohydrate Intake

A high-fiber diet may reduce enterohepatic recirculation of estrogens. Gut bacteria with beta-glucuronidase activity deconjugate excreted estrogens in the colon, allowing reabsorption. Studies examining the estrobolome suggest that a fiber-rich, plant-forward diet supports a gut microbiome that favors estrogen excretion over recirculation. Cruciferous vegetables contain indole-3-carbinol, which shifts estrogen metabolism toward less active 2-hydroxylated metabolites, though most human trials are small and this mechanism is not yet confirmed at a clinical-practice level.

3. Limit Alcohol

Alcohol inhibits hepatic estrogen metabolism and acutely raises circulating estrogen levels. A meta-analysis of 53 studies found that each additional 10 g of alcohol per day was associated with measurable increases in serum estrone in postmenopausal women. Reducing alcohol intake is one of the most modifiable dietary factors affecting E1.

4. Aromatase Inhibitors (Oncologic Context)

Aromatase inhibitors (AIs), including anastrozole, letrozole, and exemestane, are used in hormone receptor-positive breast cancer to suppress postmenopausal estrogen production to near-undetectable levels. The ATAC trial demonstrated that anastrozole 1 mg daily over five years reduced recurrence rates compared to tamoxifen in postmenopausal women with early breast cancer. AIs are not indicated for E1 reduction outside of an oncologic indication. They carry significant risks including accelerated bone loss and severe musculoskeletal symptoms.

How to Raise Estrone (E1): Evidence-Based Approaches

Low E1 in postmenopause or in women with ovarian insufficiency can contribute to bone loss, GSM, and vasomotor symptoms. The goals of treatment are symptom relief and tissue protection, not normalization of a number.

1. Hormone Therapy: Systemic Estrogen

The 2023 Menopause Society hormone therapy position statement affirms that for women under 60 or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks when used for bothersome vasomotor symptoms, GSM, or prevention of bone loss in women at elevated fracture risk.

Oral estradiol is converted substantially to estrone by first-pass hepatic metabolism, producing a circulating E1:E2 ratio of approximately 3:1 to 5:1. Transdermal estradiol bypasses this conversion and delivers a ratio closer to 1:1, resembling the premenopausal state more closely. A pharmacokinetic study in Menopause confirmed that transdermal delivery produces significantly lower E1 relative to E2 compared to oral delivery at equivalent symptom-relief doses.

If the goal is raising total estrogenic exposure, either route will raise E1. If the goal is a more physiologic estrogen profile, transdermal is preferred.

2. Weight-Bearing Exercise for Bone Protection Alongside Low E1

Exercise does not raise E1 directly. In women with low E1, the bone-protective role that estrogen normally provides must be partially supplemented through mechanical loading. The LIFTMOR trial demonstrated that supervised high-intensity resistance and impact training significantly improved bone mineral density at the lumbar spine and femoral neck in postmenopausal women with low bone mass. This does not replace estrogen therapy in women with symptomatic deficiency, but it is an important adjunct.

3. Managing Premature Ovarian Insufficiency (POI)

Women with POI are diagnosed before age 40 and face decades of estrogen deficiency. ACOG Committee Opinion No. 698 recommends that women with POI receive hormone therapy at least until the average age of natural menopause (approximately 51 years) to protect bone, cardiovascular, and cognitive health. The E1 of a woman with POI on appropriate hormone therapy will reflect her exogenous estrogen rather than ovarian production.

The WomanRx E1 Action Framework by Life Stage

| Life stage | E1 direction of concern | Primary clinical lever | |---|---|---| | Reproductive years with PCOS | Elevated relative to E2 | Address androgen excess; weight management | | Perimenopause | Variable; E2 falling faster | Monitor FSH and E2 together; assess symptoms | | Early postmenopause, symptomatic | Low | Consider systemic HRT; transdermal preferred | | Postmenopause, elevated BMI | Elevated | Weight reduction; limit alcohol | | Breast cancer survivorship on AI | Suppressed | Bone protection; musculoskeletal monitoring | | POI | Low | HRT until age 51; bone and CV monitoring |

Pregnancy, Lactation, and Contraception

Estrone is not a therapeutic drug, so there is no pregnancy category or lactation transfer risk tied to E1 itself. However, understanding E1 in the context of pregnancy and postpartum matters.

During Pregnancy

All three estrogens rise dramatically in pregnancy. By the third trimester, circulating estrone concentrations can exceed premenopausal values by ten-fold or more, driven primarily by placental aromatization of fetal and maternal androgens. Estrogen levels in pregnancy are reviewed in a 2005 Endocrine Reviews article that describes the placenta as the dominant estrogen-producing organ from the second trimester onward. Measuring E1 in pregnancy is rarely clinically useful because the range is so wide and trimester-specific normal values differ substantially from non-pregnant norms.

Postpartum and Lactation

After delivery and placenta expulsion, all estrogens fall sharply. Breastfeeding suppresses hypothalamic-pituitary-ovarian signaling through prolactin, keeping E1 and E2 low for the duration of full lactation. This lactational hypoestrogenism is responsible for postpartum vaginal dryness and dyspareunia. It resolves as breastfeeding frequency decreases and ovarian function resumes.

Aromatase Inhibitors and Contraception

Women of reproductive age who are prescribed aromatase inhibitors for conditions such as ovarian stimulation protocols in fertility care (letrozole is used off-label for ovulation induction in PCOS) face specific reproductive considerations. ASRM practice guidelines on letrozole for ovulation induction note that letrozole should not be used in women who may be pregnant and that contraception is required for non-conception cycles in women not actively trying to conceive with medical oversight.

Anastrozole and exemestane are teratogenic in animal models. Women of childbearing potential prescribed these agents for any indication should use reliable non-estrogen-containing contraception.

Who This Applies To and Who It Does Not

Women Who Should Monitor E1

• Postmenopausal women with symptoms of estrogen deficiency (hot flashes, GSM, mood changes, bone loss) and no clear cause
• Women on aromatase inhibitors who need confirmation of adequate estrogen suppression
• Women with PCOS and unexplained menstrual irregularity when standard testing is inconclusive
• Women with suspected estrogen-secreting adrenal or ovarian tumors (E1 is part of the panel, not the sole marker)
• Women with POI monitoring adequacy of hormone therapy

When E1 Alone Is Not Enough

E1 as a standalone result is rarely the clinical answer. It must be interpreted with estradiol, FSH, LH, and often testosterone and SHBG. The Endocrine Society clinical practice guideline on menopause does not recommend routine measurement of estrone to diagnose menopause; FSH and estradiol together with clinical history are the standard approach.

Ordering an E1 level without clinical context is a common source of patient confusion. If your provider ordered this test without explaining why, that is a reasonable thing to ask them to clarify.

Lifestyle Factors That Affect E1 Across Life Stages

Sleep and Cortisol

Chronic poor sleep elevates cortisol, which can alter adrenal androgen output and shift the substrate available for aromatization. A 2015 study in Sleep Medicine showed that sleep disruption in perimenopausal and postmenopausal women correlated with increased adrenal androgen activity. While a direct E1 elevation from sleep deprivation has not been established in large trials, the adrenal androgen pathway is a plausible mechanism.

Phytoestrogens: Modest and Contested Evidence

Soy isoflavones bind estrogen receptors with weak agonist and antagonist activity depending on tissue context. Their effect on measured serum E1 is minimal and inconsistent across studies. A Cochrane review of phytoestrogens for menopausal symptoms found modest benefit for vasomotor symptoms in some preparations but no clear evidence of clinically meaningful changes in circulating estrogen levels. Dietary soy is safe for most women, including breast cancer survivors in most current guidelines, but it is not an effective way to raise or lower your E1 result.

Thyroid Function

Hypothyroidism slows hepatic estrogen metabolism, which may raise circulating E1. Women with untreated or undertreated hypothyroidism, a condition that affects women at roughly five to eight times the rate seen in men, may have secondarily elevated estrogen levels that normalize once thyroid function is corrected. If your E1 is elevated and you have not had a thyroid panel recently, that is worth discussing with your provider.